Abstract
Background Accessible datasets are of fundamental importance to the advancement of Alzheimer’s disease (AD) research. The AddNeuroMed consortium conducted a longitudinal observational cohort study with the aim to discover AD biomarkers. During this study, a broad selection of data modalities was measured including clinical assessments, magnetic resonance imaging, genotyping, transcriptomic profiling and blood plasma proteomics. Some of the collected data were shared with third-party researchers. However, this data was incomplete, erroneous and lacking in interoperability.
Methods We systematically addressed several limitations of the originally shared data and provide additional unreleased data to enhance the patient-level dataset.
Results In this work, we publish and describe ANMerge, a new version of the AddNeuroMed dataset. ANMerge includes multimodal data from 1702 study participants and is accessible to the research community via a centralized portal.
Conclusions ANMerge is an information rich patient-level data resource that can serve as a discovery and validation cohort for data-driven AD research, such as for example machine learning and artificial intelligence approaches.
ANMerge can be downloaded here: https://doi.org/10.7303/syn22252881
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project has received partial support from the Innovative Medicines Initiative Joint Undertaking "AETIONOMY" under grant agreement #115568, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution. This project was partially funded by an MRC Mental Health Data Pathfinder Award to the University of Oxford (MC_PC_17215), and supported by the NIHR Oxford Health Biomedical Research Centre. The original AddNeuroMed study was supported by InnoMed (Innovative Medicines in Europe), an Integrated Project funded by the European Union of the Sixth Framework program priority FP6-2004-LIFESCIHEALTH-5, Life Sciences, Genomics, and Biotechnology for Health. Additional support for data collection was granted by the Alzheimer's Research Trust and from the NIHR Specialist Biomedical Research Centre for Mental Health at the South London and Maudsley NHS Foundation Trust and King's College London, Institute of Psychiatry, London, United Kingdom.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data collection was performed in following the Declaration of Helsinki and informed consent was gathered. Data were already published previous to this work and participants agreed to publication to generate the most societal benefit.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available under: https://doi.org/10.7303/syn22252881
